Home  »  Stocks to Trade   »  December 12th Ratings Updates: Carvana Co (CVNA), ...

December 12th Ratings Updates: Carvana Co (CVNA), Iovance Biotherapeutics Inc. (IOVA), Fidelity National Information Services Inc. (FIS)

It is important to note that analyst upgrades and downgrades can have a significant impact on a stock’s price. Stocks like these can result in short-term profits, but can also result in investment losses if analysts misjudge them.

There are three tiers of stock ratings used by analysts:

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


When analysts rate a stock as BUY, it will perform better than the market. The analyst can also use terms like overweight and outperform to describe their ratings.

If analysts anticipate that a stock will perform similarly to the market, a “Hold” rating would be assigned to it. Stocks with a hold rating are not recommended for selling or buying at the time. “HOLD” ratings are also known as Equal Weight or Market Perform.

When analysts expect a stock to disappoint, they label it as a “Sell.” For the most part, analysts rate stocks positively or neutrally rather than calling them “Sell”.” Underweight” and “Underperform” are other terms that can also be used for a “Sell” rating.

Looking at the support for the Carvana Co (NYSE: CVNA), a number of firms have released research notes about the stock. Needham stated their Hold rating for the stock in a research note on December 09, 2022. William Blair’s coverage for the Carvana Co. (CVNA) stock in a research note released on December 07, 2022, offered an Mkt perform rating. Wedbush was of a view on December 07, 2022, that the stock is underperforming, while BofA Securities gave the stock a Neutral rating on November 30, 2022, issuing a price target of $43- $10. Robert W. Baird on their part issued a Neutral rating on November 22, 2022.

The shares of Iovance Biotherapeutics Inc. (NASDAQ: IOVA) have been pegged with a rating of Neutral by Goldman in its latest research note that was published on December 09, 2022. The Healthcare company has also assigned a $6 price target. Goldman wasn’t the only research firm that published a report on Iovance Biotherapeutics Inc., with other equities research analysts also giving their opinion on the stock. Guggenheim advised investors in its research note published on October 31, 2022, to “a Neutral,”. The stock earned an Equal Weight rating from Wells Fargo when it published its report on August 18, 2022. That day Wells Fargo set a price target on the stock to $14. The stock was given a Buy rating by Stifel in its report released on January 28, 2022, the day when the price target on the stock was placed at $25. Cowen was of the view that IOVA is Outperforming in its latest report on December 07, 2021. JMP Securities thinks that IOVA is worth Mkt Outperform rating. This was contained in the firm’s report on June 10, 2021, in which the stock’s price target was also moved to 32.

Investment analysts at Jefferies published a research note on December 09, 2022, where it informed investors and clients that Fidelity National Information Services Inc. (NYSE: FIS) is now rated as Hold. Their price target on the stock stands at $75. Wolfe Research also rated FIS as downgraded on November 04, 2022. Even though the stock has been trading at $69.79/share, analysts expect it to up by 0.69% to reach $70.27/share.

Leave a Comment

Your email address will not be published. Required fields are marked *